Table 3.
Scleroderma-specific antibodies and pulmonary function and echocardiography values in patients with Pre-PAH. Autoantibody data were available for 127/166 Pre-PAH patients. Pre-PAH patients were divided according to the 3 most commonly present autoantibodies to determine the association between scleroderma-specific antibodies and clinical PAH markers. The other patients did not have detectable autoantibodies or had an anti-U1-RNP, anti-RNA polymerase III, other, or no autoantibody information was available. A patient without an SSc-specific antibody who had multiple ANA patterns was characterized as “other.” There were no statistically significant differences between groups.